BUZZ-ADMA Biologics rises after rejecting short-seller's claims

Reuters03-27

BUZZ-<a href="https://laohu8.com/S/ADMA">ADMA Biologics</a> rises after rejecting short-seller's claims

** Shares of biotech firm ADMA Biologics ADMA.O rise 12.44% to $9.32 premarket

** Co issues statement against a March 24 report by short seller Culper Research, rejecting what it called false and misleading claims about its business

** Says demand for Asceniv, its antibody treatment for immune-deficient patients, has been rising for more than two years and is now at a record high

** Says the amount of product held by distributors is normal for the industry and reflects the need to keep enough supply on hand because the drug takes a long time to make

** Adds it received clean audit opinions for 2024 and 2025 and there have never been any undisclosed related party transactions in violation of U.S. securities laws

** ADMA shares were up over 6% in 2025

(Reporting by Kunal Das in Bengaluru)

((Kunal.Das2@thomsonreuters.com;))

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2622243048?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-27 21:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2622243048","market":"nz","top_or_hot":-1,"title":"BUZZ-ADMA Biologics rises after rejecting short-seller's claims","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-<a href=\"https://laohu8.com/S/ADMA\">ADMA Biologics</a> rises after rejecting short-seller's claims</title></head><body><p>** Shares of biotech firm ADMA Biologics <span>ADMA.O</span> rise 12.44% to $9.32 premarket </p><p>** Co issues statement against a March 24 report by short seller Culper Research, rejecting what it called false and misleading claims about its business</p><p>** Says demand for Asceniv, its antibody treatment for immune-deficient patients, has been rising for more than two years and is now at a record high</p><p>** Says the amount of product held by distributors is normal for the industry and reflects the need to keep enough supply on hand because the drug takes a long time to make</p><p>** Adds it received clean audit opinions for 2024 and 2025 and there have never been any undisclosed related party transactions in violation of U.S. securities laws</p><p>** ADMA shares were up over 6% in 2025 </p><p> (Reporting by Kunal Das in Bengaluru)</p><p> ((Kunal.Das2@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-ADMA Biologics rises after rejecting short-seller's claims</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-ADMA Biologics rises after rejecting short-seller's claims\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-27 21:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-<a href=\"https://laohu8.com/S/ADMA\">ADMA Biologics</a> rises after rejecting short-seller's claims</title></head><body><p>** Shares of biotech firm ADMA Biologics <span>ADMA.O</span> rise 12.44% to $9.32 premarket </p><p>** Co issues statement against a March 24 report by short seller Culper Research, rejecting what it called false and misleading claims about its business</p><p>** Says demand for Asceniv, its antibody treatment for immune-deficient patients, has been rising for more than two years and is now at a record high</p><p>** Says the amount of product held by distributors is normal for the industry and reflects the need to keep enough supply on hand because the drug takes a long time to make</p><p>** Adds it received clean audit opinions for 2024 and 2025 and there have never been any undisclosed related party transactions in violation of U.S. securities laws</p><p>** ADMA shares were up over 6% in 2025 </p><p> (Reporting by Kunal Das in Bengaluru)</p><p> ((Kunal.Das2@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260327:nL4N40F0YP:1","article_id":"2622243048","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2622243048","pubTimestamp":1774616414,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-ADMA Biologics rises after rejecting short-seller's claims** Shares of biotech firm ADMA Biologics ADMA.O rise 12.44% to $9.32 premarket ** Co issues statement against a March 24 report by short seller Culper Research, rejecting what it called false and misleading claims about its business** Says demand for Asceniv, its antibody treatment for immune-deficient patients, has been rising for more than two years and is now at a record high** Says the amount of product held by distributors is normal for the industry and reflects the need to keep enough supply on hand because the drug takes a long time to make** Adds it received clean audit opinions for 2024 and 2025 and there have never been any undisclosed related party transactions in violation of U.S. securities laws** ADMA shares were up over 6% in 2025   ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","ADMA":"ADMA Biologics Inc"},"translate_title":"BUZZ-ADMA Biologics在拒绝卖空者的说法后股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ADMA":0.9},"content_text":"BUZZ-ADMA Biologics rises after rejecting short-seller's claims** Shares of biotech firm ADMA Biologics ADMA.O rise 12.44% to $9.32 premarket ** Co issues statement against a March 24 report by short seller Culper Research, rejecting what it called false and misleading claims about its business** Says demand for Asceniv, its antibody treatment for immune-deficient patients, has been rising for more than two years and is now at a record high** Says the amount of product held by distributors is normal for the industry and reflects the need to keep enough supply on hand because the drug takes a long time to make** Adds it received clean audit opinions for 2024 and 2025 and there have never been any undisclosed related party transactions in violation of U.S. securities laws** ADMA shares were up over 6% in 2025  (Reporting by Kunal Das in Bengaluru) ((Kunal.Das2@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2622243048","isCrawlerRequest":true}